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Background. Eosinophilic cholangitis (EC) is a rare benign disorder of the biliary tract which can cause biliary obstruction.
Similar to other disease processes involving the bile ducts, this disorder can pose a difficult diagnostic challenge as it can
mimic cholangiocarcinoma. Methods. A systematic search of the scientific literature was carried out using PubMed to access all
publications related to EC. Search keywords that were utilized included “eosinophilic cholangitis,” “etiology,” “treatment,” and
“obstructive jaundice.” Results. Twenty-three cases of EC have been reported. Nineteen patients (82.6%) who presented with EC
remain disease-free; 15 of these 19 patients (78.9%) with followup time remain disease-free at a mean of 9.7 months (range, 2–24
months). Conclusion. EC is a rare form of biliary obstruction which can masquerade as a malignancy. Unlike cholangiocarcinoma,
EC occurs more commonly in younger patients and in men. Most patients will require surgical treatment.
1. Introduction
A variety of biliary conditions can mimic cholangiocarci-
noma (CCA) and the precise pathologic distinction between
benign and malignant causes of common hepatic duct
(CHD), and proximal biliary tract obstruction remains a
challenging clinical problem. In addition to malignant causes
such as hilar CCA, lymphoma, gallbladder carcinoma, and
metastases, benign causes of biliary obstruction include, but
are not limited to: autoimmune pancreatitis-associated scle-
rosing cholangitis, extrahepatic primary sclerosing cholan-
gitis (PSC), Mirizzi syndrome, inflammatory strictures sec-
ondary to choledocholithiasis, idiopathic benign focal stric-
ture, and acquired immune deficiency syndrome cholangitis
[1–6]. Approximately 10% of patients who undergo surgery
for hepatic hilar strictures are found to have benign disease
[1, 2]. Hadjis and colleagues initially coined the term
“malignant masquerade” in 1985 to emphasize how benign
entities can be difficult to distinguish from hilar CCA, in both
clinical presentation and radiological appearance [1].
Eosinophilic cholangitis (EC) is an extremely rare benign
disorder of the biliary tract which can result in biliary
obstruction [3–5, 7, 8]. This disorder must be distinguished
from CCA, which can be difficult since it is characterized
by a dense transmural eosinophilic infiltration of the bile
duct. A comprehensive literature review identified only 22
cases of EC [2–4, 8–24]. In this paper, we discuss an
additional case involving a 33-year-old man who presented
with obstructive jaundice and a mid-bile duct stricture
(Bismuth-Corlette Type III). Extensive radiologic and endo-
scopic evaluation failed to yield a pathologic diagnosis,
and common bile excision with Roux-en-Y hepaticojejunos-
tomy, cholecystectomy, and portal lymphadenectomy was
performed. Histopathology revealed a dense eosinophilic
infiltration of the extrahepatic bile duct that was consistent
with EC. A review of the literature and a discussion of the
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clinical presentation, diagnosis, management, and prognosis
of patients with EC are provided.
2. Case Report
A 33-year-old Caucasian man presented with a two-month
history of fatigue, jaundice, severe pruritis, and steatorrhea.
He noted a 10–15 pound weight loss over the prior two
months but denied nausea, vomiting, abdominal pain, fever,
or chills. Past medical history was significant for hyperlipi-
demia, with no history of biliary tract disease or ulcerative
colitis (UC). Family history was negative for inflammatory
bowel disease (IBD) or gastrointestinal (GI) malignancies.
There was no history of foreign travel or significant allergic
or atopic reactions. Physical exam disclosed no abnormalities
except for scleral icterus and mild tenderness on deep pal-
pation in the right upper quadrant (RUQ) of his abdomen.
Pertinent laboratory tests revealed elevated liver function
tests (LFTs): aspartate aminotransferase, 75 IU/L; alanine
aminotransferase, 208 IU/L; alkaline phosphatase, 337 IU/L;
gamma-glutamyl transferase, 1166 IU/L; total bilirubin,
5.2mg/dl, and direct bilirubin, 4.65mg/dl. Amylase and
lipase levels were 52 IU/L and 250 IU/L, respectively. Total
white blood cell count was 5.4 × 103/mm3, with a dif-
ferential cell count of 56% neutrophils, 32% lymphocytes,
and 2% eosinophils. The patient’s hemoglobin, hematocrit,
and platelet counts were 13.5 gm/dl, 41.6%, and 354 ×
103/mm3, respectively. Hepatitis virus screening, tumor
and immunological markers including carcinoembryonic
antigen (CEA) and carbohydrate antigen 19-9 (CA19-9),
and antinuclear (ANA), antimitochondrial (AMA), and
antismoothmuscle (ASM) antibodies were all unremarkable.
Immunoglobulin G (IgG) quantitative levels were also neg-
ative, all but ruling out autoimmune sclerosing cholangitis
as a possible diagnosis. Ultrasonography (US) of the RUQ
revealed a normal gallbladder with no evidence of gallstones
and markedly dilated intrahepatic and extrahepatic bile
ducts down to the level of mid-common bile duct (CBD).
These findings were confirmed by a computed tomography
(CT) scan of the abdomen and pelvis and a magnetic
resonance cholangiopancreatography (MRCP) which further
demonstrated a focal stricture of the CHD at the level
of the cystic duct entry (Figure 1). The left and right
intrahepatic ducts measured 13mm and 14mm, respectively.
The CBD and pancreatic duct were normal in caliber. An
endoscopic retrograde cholangiopancreatography (ERCP)
was performed, at which time the biliary stricture was
dilated and a silastic biliary endoprostheis was inserted.
Brush biopsy obtained during ERCP revealed no malignant
cells. Esophagogastroduodenoscopy (EGD) revealed only
mild reflux esophagitis. In order to exclude the possibility of
concurrent undiagnosed UC, a colonoscopy with ileoscopy
and biopsy was performed which revealed a normal colon
with no evidence of colitis. An endoscopic US (EUS) demon-
strated a mass in the proximal CHD with wall thickness
of 4.7mm. EUS-guided fine needle aspiration (FNA) of
the mass showed marked inflammatory changes along with
clusters of atypical ductal cells. The patient underwent
Figure 1: Endoscopic retrograde cholangiopancreatography
(ERCP) showing focal stricture of the common hepatic duct at the
level of entry in to the cystic duct.
spy cholangioscopy, which confirmed a CHD stricture, yet
additional biopsy sampling for cytology and fluorescent in
situ hybridization (FISH) yielded only atypical cells with no
pathologic diagnosis.
In order to exclude the possibility of a malignancy, the
patient subsequently underwent an exploratory laparotomy,
cholecystectomy, portal lymphadenectomy, and an en bloc
resection of the entire CBD from the supraduodenal aspect to
the hilar bifurcation. Frozen section revealed no evidence of
malignancy. An intraoperative liver biopsy revealed normal
hepatic architecture with no evidence of PSC or granu-
lomas. The bilioenteric anastomosis was reconstructed via
a Roux-en-Y hepaticojejunostomy. Histopathology revealed
thickening of the CBD wall with periductal fibrosis and
a pronounced inflammatory cellular infiltrate comprised
almost entirely of eosinophils (Figures 2(a), 2(b), and
2(c)). The gallbladder was unremarkable and contained no
gallstones. A total of 12 benign lymph nodes were harvested.
The patient’s postoperative recovery was uneventful, and he
was discharged home on postoperative day five. At 40-month
follow-up, the patient remains asymptomatic with normal
LFTs.
3. Results
Twenty-three cases of EC have been documented, including
the current case. Available demographic, clinic, and follow-
up data are presented in Table 1. Among this group are
14 men and nine women (M : F = 1.6 : 1) with an overall
mean age of 39.4 years (range, 13–67 years). The mean
age among men was 35.4 years (range, 13–55 years), and
the mean age among women was 45.8 years (range, 16–67
years). Abdominal pain was the most common presenting
complaint (74%), followed by jaundice (61%). Among the 23
patients, 16 (69.6%) demonstrated peripheral eosinophilia
while seven (30.4%) had normal serum eosinophil counts.
Eight of the 23 patients (34.8%) had complete resolution
of symptoms with surgery alone, seven patients (30.4%)
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Figure 2: (a) Low power magnification displaying a common bile duct wall with bile duct mucosal glands, composed of columnar cells
with basally oriented nuclei and subepithelial collagen. There is no epithelial atypia. The subepithelial area shows periductal fibrosis and
pronounced diffuse inflammatory cellular infiltrate. White circle indicates infiltrate. (Hematoxylin and Eosin stain; (b) displaying 20x; (c)
displaying 40x magnification). (b) and (c) Higher-power view demonstrating bile duct mucosal glands composed of columnar cells with
basally oriented nuclei. In the subepithelial region, there is a dense infiltrate comprising predominantly of eosinophils, identified by their
pathognomonic cytoplasmic granules and bilobed nuclei. The eosinophils are present diffusely within the stroma and around the glands.
However, in some areas, these cells form clusters of four to five cells. The white arrows demonstrate the clusters of eosinophils. Along with the
eosinophils, other inflammatory cells are also identified, including lymphocytes with scanty cytoplasm and small hyperchromatic dark blue
nuclei as well as the larger neutrophils with their granular cytoplasm and multilobed nuclei. (Hematoxylin and Eosin stain; 1b displaying
20x; 1c displaying 40x magnification).
improved with the use of oral corticosteroids, and another
six patients (26.1%) achieved complete resolution with a
combination of surgery and oral corticosteroids. One patient
(4.3%) achieved symptom resolution with hydroxyurea
treatment, after repeated high-dose steroid therapy was
only temporarily successful. Lastly, one patient (4.3%) who
presented with EC secondary to infection with Echinococcus
(hydatid disease) achieved complete resolution of symptoms
with albendazole treatment for a total of two weeks followed
by surgical treatment which consisted of aspiration of the
hydatid cyst and a left hepatic lobectomy. Fifteen of the
19 patients (78.9%) with reported follow-up time remain
disease-free with a mean follow-up of 9.7 months (range, 2–
24 months).
4. Discussion
EC was first reported by Leegaard in 1980 [9]. Although
the cause of this disorder remains unknown, it appears to
be a benign, self-limiting disease. Underlying infections with
Enterobacter aerogenes in one patient and Candida albicans in
another have been postulated as a cause for the eosinophilic
infiltration [2, 10]. However, each of the two above-
mentioned patients had undergone prior instrumentation of
the biliary tree; [2, 10] therefore, it seems most likely that
the biliary infections were secondary events rather than the
primary cause of the inflammatory process. It has also been
noted that gallstones within the biliary system may act as
irritant foci which results in eosinophilic infiltration in some
patients [10, 25]. Several studies have demonstrated a link
between hypereosinophilia and bile duct fibrosis. Wong and
colleagues suggested that eosinophils produce transforming
growth factor-β, a cytokine capable of inducing fibrosis [26].
Although a number of theories have been postulated, the
precise pathogenesis of the eosinophilic infiltration is poorly
understood.
Eosinophilic cholangiopathy is part of a larger spectrum
of disorders characterized by eosinophilic infiltration of tis-
sues and organ systems with or without concomitant periph-
eral eosinophilia. In this spectrum of disorders, all patients
have one thing in common: unexplained eosinophilic
proliferation. However, the severity and prognosis of the
disorder vary between patients. The most severe pathology
in this spectrum of diseases is idiopathic hypereosinophilic
syndrome (IHES) which involves eosinophilic infiltration of
the bone marrow and other organs. IHES is characterized
by (1) persistent eosinophilia of 1.5 × 109/L for at least
six months or any eosinophilia leading to death within six
months; (2) lack of a recognized cause for the eosinophilia,
including parasitic infections, collagen vascular diseases, and
allergies; (3) organ system involvement or dysfunction due to
eosinophilic infiltration or eosinophilia-associated damage
[27, 28]. Multiorgan involvement is described in themajority
of patients who present with biliary tract involvement and
may include infiltration of the pancreas, liver, GI tract,
ureters, and kidneys [4, 12–14]. There is no clear relationship
between IHES and EC, which is not usually described
as part of this syndrome. It remains unclear as to the
pathophysiology of eosinophilic recruitment to the biliary
tract in IHES. However, it seems that the presence of these
eosinophils is directly related to the disease process, possibly
via direct cytotoxicity, as they may release free radicals or
tissue-damaging proteins [11]. The diagnosis of end-organ
involvement is essential in IHES as the course of the disease
may be variable. The disease may rapidly progress, eventually
causing hepatotoxicity and fibrosis, and ultimately leading
to the need for liver transplantation [11]. If caught early,
however, corticosteroid therapy has been beneficial in up to
69% of patients with IHES [11].
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Table 1: All reported cases of eosinophilic cholangitis.
Case Study
Gender age (yrs)
Presenting symptoms Eos. Treatment Status
Age Sex
1 Rodgers et al., [2] 2001 50 F Abdominal pain No
Roux-en-Y,
CE
NED, 2 mos
2 Matsumoto et al., [3] 2007 38 F
Abdominal pain,
jaundice
Yes CS NED, 5 mos
3 Vauthey et al., [4] 2003 44 M
Abdominal pain,
jaundice
Yes CS NED, 18 mos
4 Duseja et al., [8] 2005 16 F
Abdominal pain,
jaundice
Yes CS NED, 12 mos
5 Leegaard, [9] 1980 46 M
Abdominal pain,
jaundice
No CE, CS NED, 18 mos
6 Rosengart et al., [10] 1990 48 M
Abdominal pain,
jaundice
No CE NED, 5 mos
7 Al-Abdulla et al., [11]
2000
42 F Abdominal pain,
jaundice
Yes CE, CS NED
8 Platt et al., [12] 1990 56 F
Jaundice, ureteric
obstruction
No CE N/A
9 Schoonbroodt et al., [13]
1995
20 M Jaundice, fever Yes CE, CS Recurred in stomach
10 Grauer et al., [14] 1993 41 M
Abdominal pain,
jaundice, fever
Yes CS, Ursodiol Recurred in kidney
11 Jimenez-Saenz et al., [15]
2003
67 F Abdominal pain,
jaundice
Yes CE, CS NED, 12 mos
12 Butler et al., [16] 1985 32 M Abdominal pain Yes CE NED, 24 mos
13 Tenner et al., [17] 1997 38 F Abdominal pain Yes CE, CS NED, 3 mos
14 Shanti et al., [18] 2001 33 M
Abdominal pain,
jaundice
No CE, hepatico-
jejunostomy
NED, 3 mos
15 Shanti et al., [18] 2001 57 F
Abdominal pain,
jaundice
No Roux-en-Y NED, 6 mos
16 Song et al., [19] 1997 48 F Abdominal pain Yes CE, T-tube NED, 9 mos
17 Scheurlen et al., [20] 1992 28 M
Abdominal pain,
diarrhea
Yes Hydroxurea NED
18 Chen et al., [21] 2009 55 M Jaundice Yes
Roux-en-Y,
CE, CS
NED, 9 mos
19 Jeyamani et al., [22] 2007 13 M Fever Yes CS Recurred in liver
20 Jeyamani et al., [22] 2007 26 M Fever, pruritis Yes CS NED, 6 mos
21 Sussman et al., [23] 2008 52 M Abdominal pain, pruritis Yes
CS, AZT,
UDCA
NED
22 Raptou et al., [24] 2009 24 M Abdominal pain, fever Yes
Aspiration,
Albendazole
NED
23 Current study, 2009 33 M Jaundice, pruritis No
Roux-en-Y,
CE, portal
lymph-
adenectomy,
common bile
excision
NED, 13 mos
Note. Eos: Eosinophilia; CS: Corticosteroids; CE: Cholecystectomy; AZT: Azathioprine; UDCA: Ursodeoxycholic acid; N/A: Not available; NED: No evidence
of disease.
Eosinophilic gastroenteritis (EGE) is a separate disease in
this spectrum characterized by eosinophilic infiltration of the
wall of the GI tract. EGE is thought to be associated with
EC and may result from an allergic mechanism in 37%–41%
of cases [3, 29]. EGE most commonly affects the stomach
and proximal small bowel but may involve nearly every GI
organ [29, 30]. EGE is characterized by (1) eosinophilic
infiltration of one or more segments of the GI tract; (2) the
presence of GI symptoms; (3) no recognizable cause for the
eosinophilic infiltration; (4) no extradigestive involvement;
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(5) variable peripheral eosinophilia [30]. Although the
most common symptoms of EGE are nausea, vomiting,
diarrhea, and abdominal pain, the clinical manifestations of
EGE vary depending on the area of the GI tract involved.
Mucosal involvement manifests as weight loss secondary to
malabsorption, steatorrhea, iron-deficiency anemia, blood
loss, and protein-losing enteropathy, whereas involvement of
the muscularis propria presents with obstructive symptoms,
and subserosal disease results in eosinophilic ascites [15, 30].
The diagnosis of EC is a difficult one and is based solely
on histological findings. Matsumoto et al. have proposed
the following criteria to correctly diagnose EC: (1) wall
thickening or stenosis of the biliary system; (2) histopatho-
logical findings of eosinophilic infiltration; (3) reversibility
of biliary abnormalities without treatment or following
steroid treatment [3]. Although the presence of peripheral
eosinophilia may be a clue to the diagnosis of EC, it is neither
sensitive nor specific of dense eosinophilic infiltration of the
bile duct [2]. Laboratory values, including tumor markers,
are useful in distinguishing between benign and malignant
biliary obstruction but are usually unable to determine the
exact cause of a biliary stricture [6]. The accuracy of fast liver
alkaline phosphatase isoenzyme in differentiating between
benign and malignant causes of extrahepatic obstruction has
been reported to be up to 80% [31]. Tumor markers, such as
CEA and CA19-9, have been used to distinguish CCA from
other causes of obstruction, but they exhibit highly variable
sensitivity and specificity [31–33]. An elevated CA19-9 level
is not specific for a malignant process, as high circulating
levels are noted in a variety of benign conditions including
ascending cholangitis, pancreatitis, and other benign cases of
obstructive jaundice [31–33].
A variety of modalities are currently available to view
and evaluate the biliary system. Noninvasive radiological
modalities include US, contrast-enhanced CT (CECT) scan,
magnetic resonance imaging (MRI), and MRCP can provide
useful information about the level of obstruction, extent
of biliary dilatation, and the presence of a mass or distant
metastasis [34, 35]. A common, but nonspecific finding in
the setting of EC is thickening of the bile duct wall on
US or CECT, with or without biliary dilatation [4, 19].
MRCP may demonstrate an irregular narrowing of the
bile duct, while invasive modalities such as ERCP or per-
cutaneous transhepatic cholangiography (PTC) may reveal
irregularities of the CBD wall and intrahepatic ducts [4,
19]. ERCP or PTC can also provide additional information
as to the length and site of a biliary stricture and allows
for tissue diagnosis via brush biopsy and cytology studies
[35]. EUS is an alternative modality to ERCP and PTC
which allows antegrade biliary access via an EUS-guided
needle puncture into the biliary system. This would allow
for safe cannulization of strictures, biliary drainage, and
other treatments offered by ERCP in settings of surgically-
altered biliary anatomy or biliary inflammation [36, 37].
Cytology is an important part of the diagnostic workup of
patients with eosinophilic cholangiopathy in order to rule
out the possibility of CCA. Although routine brush cytology
during ERCP has a high specificity (75%), the sensitivity
rates are highly variable, with ranges from 44% to 80%
[38, 39]. The use of FISH examination is a valuable tool for
the detection of malignancy in biliary tract strictures [39].
While traditional cytology analysis identifies abnormally-
shaped cells, FISH utilizes fluorescently-labeled DNA probes
to assess for chromosomal alterations or malignant cells.
Although cytology appears to be more specific than FISH
for the detection of malignant strictures (98% versus 91%,
resp.), Kipp and colleagues demonstrated that the sensitivity
of FISH was significantly greater than routine cytology for
bile duct brushing samples [39].
Single-operator direct cholangioscopy SpyGlass system is
a new addition to the arsenal of available technologies for
visualizing the bile ducts. It provides direct visualization of
the biliary tract and has been shown to improve the ability
to distinguish malignant from benign strictures [39, 40]. In
a study by Kurland et al., four of 17 patients with an initial
diagnosis of benign biliary strictures on cytology were found
to have malignant strictures with SpyGlass-directed biopsies
[39]. Overall, spy-directed biopsies has a sensitivity and
specificity of 62.5% and 100%, respectively, using positive
cytology or surgical biopsy as the reference standard [39].
Despite these efforts, precise tissue diagnosis in the setting of
EC is typically not possible, and surgery is usually necessary
to exclude CCA.
Although EC is a benign self-limiting disease, the
difficulty involved with excluding malignancy, and the
variable course of the disease, makes precise treatment
recommendations difficult [4, 16, 25]. Two reported cases
of EC experienced spontaneous regression of the CHD
stricture on repeat cholangiography within three weeks
without any specific treatment [10, 16]. Although the role of
steroids and hydroxyurea remains unclear, there are several
cases of successful treatment with oral corticosteroids alone
[3, 4, 8] (refer to Table 1). The suggested mechanism of
action for corticosteroids in the treatment of eosinophilic
cholangiopathy is unknown, yet Butler et al. reported that a
“diagnostic” trial of oral corticosteroids may be considered
prior to surgical intervention [16]. Despite the success of
nonsurgical therapy in some cases, surgery is an effective
and a definitive means of treatment for EC [29] and is
obligatory if malignancy cannot be excluded. Fourteen of the
23 published cases were treated surgically.
5. Conclusions
Obstructive jaundice due to a mid or proximal biliary stric-
ture poses substantial diagnostic and management issues. EC
is a benign process capable of masquerading as a malignancy
and posing substantial diagnostic challenges. The diagnosis
of EC is difficult to conclusively make and often requires
an extensive workup as in the current case. Despite its
rarity, EC should be considered when imaging modalities
demonstrate a narrowing of the extrahepatic bile duct(s)
with marked wall thickening, especially in the setting of
peripheral eosinophilia. Based on evidence of disease regres-
sion with oral corticosteroids, a course of oral corticosteroids
is the initial recommended therapy. If diagnostic uncertainty
persists, however, surgery is mandatory and curative in all
reported cases.
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